Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label randomized study of LP-005 in paroxysmal nocturnal hemoglobinuria
CTR20242478Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by LongBio Pharma. Started Nov 2024; status: active.
02
Drugs
LP-005
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20242478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242478.